Dr. Henry Lynch, often referred to as “The Father of Cancer Genetics”, died on June 2, 2019.

The Dana Farber Lynch Syndrome Center is dedicated to providing genetic counseling and testing to those at risk for Lynch Syndrome and delivering a new model of coordinated care for those living with Lynch Syndrome.

The Colorectal Cancer Alliance is conducting a survey open to patients, survivors and caregivers of those diagnosed with CRC before the age of 50. Help change the narrative!! Take a few minutes to complete the survey.

Dr. Jon LaPook, CBS News Medical Contributor and Professor at New York University Langone Medical School, discusses a very exciting new field of research—studying the human microbiome and it’s role in colon cancer.

According to some research, these hard to spot polyps called flat lesions are found more commonly in people who have Lynch Syndrome.

Interesting article explaining the benefits of biomarkers in colorectal cancer treatment.

For the first time, an international study showed that having normal levels of Vitamin D could actually prevent colorectal cancer (CRC).

Researchers from Memorial Sloan Kettering Cancer Center found that genomic markers can predict Lynch Syndrome across tumor types suggesting Lynch Syndrome is linked to more types of cancer than previously thought.

New screening recommendations for colorectal cancer.

Good Morning America featured a segment on colorectal cancer and it’s rise in young adults.

Heather Hampel, Ohio State University Comprehensive Cancer Center, explains how screening for Lynch Syndrome can help prevent colon cancer.

Did you know that if you were born around 1990, you have TWICE the risk of COLON cancer and QUADRUPLE the risk of RECTAL cancer than someone born around 1950? This is according to a recent study published by the American Cancer Society.

Important news if you have either the MSH6 or PMS2 Lynch Syndrome gene mutations. Researchers from Columbia University Irving Medical Center and New York Presbyterian have identified that having one of 2 gene mutations—MSH6 or PMS2—doubles a woman’s risk of developing breast cancer by age 60.

The FDA has approved the immunotherapy drug nivolumab (Opdivo) for patients with metastatic colorectal cancer that has one of two specific genetic features, high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR).

Important announcement for Lynch Syndrome cancer patients!

One of the biggest scientific breakthroughs of our time is CRISPR gene editing. It may have the power to possibly one day eliminate inherited genetic diseases like Lynch Syndrome.

Knowing you have Lynch Syndrome can save your life.

This blog from the Dana Farber Cancer Institute gives some great information about Lynch Syndrome.

The National Comprehensive Cancer Network (HCCN) recommends that all newly diagnosed colorectal cancer patients be screened for Lynch Syndrome.